Clinical Trial

A Clinical Study of Tulisokibart (MK-7240) to Treat Rheumatoid Arthritis (RA) (MK-7240-014)

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
Researchers are looking for new ways to treat rheumatoid arthritis (RA). Methotrexate (MTX) is a standard (usual) treatment for RA. However, MTX and other current treatments may not work well to treat RA symptoms for many people. This study will help find out if a study medicine called tulisokibart can treat symptoms of active RA in people who are taking MTX. In this study, researchers will look at different doses of tulisokibart. Researchers want to learn if at least one of the study doses of tulisokibart works better than a placebo to lessen RA symptoms. A placebo looks like the study medicine but has no study medicine in it. Using a placebo helps researchers better understand the effects of the study medicine.
Protocol Amendment History 3 changes
critical Trial status changed: Recruiting → Active, Not Recruiting 2026-06-13
notable Primary completion moved earlier: 2027-03-08 -> 2026-09-05 2026-06-13
minor Completion moved earlier: 2029-09-03 -> 2029-03-03 2026-06-13
Trial Details
NCT Number NCT07176390
Lead Sponsor Merck Sharp & Dohme LLC
Conditions Arthritis, Rheumatoid
Enrollment 182 participants
Start Date 2025-10-08
Primary Completion 2026-09-05 (estimated)
Study Completion 2029-03-03 (estimated)
Updated on ClinicalTrials.gov 2026-06-12